By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the past year there were no insider purchases at Collegium Pharmaceutical, Inc. Eight insiders sold roughly $7.2 million instead.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Big money check: 279 institutions held COLL as of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
Are insiders buying or selling COLL stock?
In the last 12 months Collegium Pharmaceutical, Inc insiders made open-market purchases worth about $0 and sales worth about $7.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in COLL?
The most recent open-market insider trade in COLL was filed on 2026-05-20.
How many institutions own COLL?
279 investment managers reported holding COLL in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded COLL?
No congressional trades in COLL were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).